近日，浦东创投集团参与完成上海恩凯细胞技术有限公司（简称"恩凯赛药"）A+++轮融资。恩凯赛药 募集资金将用于推进核心产品临床试验及新产品管线开发，加速NK细胞药物临床转化。 ◎记者 邓贞 谭镕 上海证券报记者梳理发现，创投市场近年频现"+++"甚至"++++""+++++"轮次，集中出现在半导体、生 物医药、具身智能、低空经济等赛道。部分创业企业难以一次性满足下一轮融资门槛，技术研发与商业 化验证周期长，遂通过多次"+轮"融资延长发展周期；同时，一级市场估值推高迹象明显，机构出手谨 慎却不愿错失好项目，于是以"小步快跑"方式完成融资。 在受访专家看来，"+轮"密集出现，意味着企业原本完整的一轮融资被拆分为两次甚至多次完成，融资 周期被动拉长。 机构出手谨慎 对于这些获得市场青睐的创业企业而言，原本拿一笔钱就能走完一个阶段的周期，为何如今却需要多次 融资？ 茹华杰介绍，按照以往对融资轮次的界定，A、B、C、D轮标准明确，代表着企业不同的发展阶段。不 同轮次间往往代表着里程碑式事件的达成，并且在估值逻辑和估值水平上有显著差异。 "++轮"融资扎堆 近两年，Pre-A+、A+、A++、B+、B++等案例屡见不鲜。 ...

Group 1: Investment and Financial Trends - As of the end of April this year, Shenzhen's private equity and venture capital funds have invested in 20,400 projects, targeting 12,500 companies nationwide, with a total investment amount of 970.275 billion yuan, showing a year-on-year increase of over 2% in early-stage, small, and hard technology projects [1] - The number of projects directed towards early-stage technology companies and the corresponding investment amount have increased by 3.89% and 3.93% year-on-year, respectively [1] Group 2: Transportation and Technology Innovations - The Hong Kong government has issued its first official taxi fleet license to Star Taxi Service Company for a period of five years, allowing the fleet to provide ride-hailing services [2] - This initiative is part of a series of measures by the Hong Kong government to optimize taxi services, aiming to establish a professional and technology-driven fleet management system [2] Group 3: Healthcare and Pharmaceutical Developments - A hospital in Shenzhen has become the first in the city to prescribe domestically developed weight-loss drugs, Ma Shidu and Te Erbo, which significantly enhance weight loss effects, especially for patients with stubborn obesity [3] - The introduction of these drugs reflects the advancement of China's biopharmaceutical industry's independent innovation capabilities and Shenzhen's pioneering efforts in medical technology applications [3] Group 4: Scientific Research and Development - China's first ocean-class intelligent research vessel, "Tongji," has been officially delivered, marking a significant advancement in marine research capabilities [4] - The vessel, which began construction in April 2024, is a 2,000-ton intelligent comprehensive research ship that will facilitate the transition from basic research to the integration of science and technology [4] Group 5: Market Performance - On July 14, the Shenzhen Composite Index closed at 10,684.52 points, down 0.11% [5] - Notable gainers in the Shenzhen market included Changrong Co. at 9.05 yuan with a rise of 20.03%, and Xinling Electric at 42.13 yuan with a rise of 19.99% [6] - Conversely, leading decliners included Yuandao Communication at 21.60 yuan, down 20.00%, and *ST Zitian at 3.52 yuan, down 17.76% [6]

Core Viewpoint - Wantaibio announced a projected net loss of 130 to 160 million yuan for the first half of 2025, marking the company's first half-year loss since its listing in 2020, primarily due to significant declines in revenue and profit in its vaccine segment caused by industry policy adjustments and market competition [2][3] Group 1: Financial Performance - The company expects a net loss of 130 to 160 million yuan for the first half of 2025, attributed to short-term sales pressure in the vaccine segment [2] - The vaccine segment's revenue and profit have significantly declined, with HPV vaccine sales dropping over 40% last year [3] - From mid-2023 onwards, the company has experienced a continuous decline in both operating revenue and net profit attributable to shareholders, with vaccine product production and sales decreasing by 13.13% and 41.94% respectively in 2023, and further declines of 64.66% and 42.40% expected in 2024 [3] Group 2: Product Development and Market Position - The newly approved "Xinkening 9," a domestic nine-valent HPV vaccine, is crucial for the company's performance recovery in the second half of the year, priced at 499 yuan per dose, which is about 40% of the price of imported counterparts [4] - The company is advancing the WHO pre-qualification process for its nine-valent HPV vaccine and has over ten products in the vaccine pipeline, including a twenty-valent pneumonia vaccine and various other vaccines in different stages of development [5][6] - The company aims to maintain its competitive edge in the HPV vaccine market by developing higher-valent HPV vaccines and focusing on a broad range of vaccine products to enhance quality of life [6]

新华社北京7月14日电 题：培育企业蓬勃生长的沃土——加快建设全国统一大市场一线观察之八 新华社记者 市场，机遇的代名词，企业的生命线。 建设全国统一大市场，是构建新发展格局、推动高质量发展的需要，是以习近平同志为核心的党中央从 全局和战略高度作出的重大决策。 市场如水，企业如鱼，水活则鱼跃。记者在近期采访中发现，各地各部门打出一系列强基础、补短板、 通梗阻的"组合拳"，加快建设高效规范、公平竞争、充分开放的全国统一大市场，助力各类经营主体蓬 勃生长，推动中国经济绽放更充沛的活力、收获更强劲的韧性。 促进竞争，打造公平"大舞台" 6月10日，浙江苍南，三澳核电项目建设迎来关键节点：1号机组"热试"圆满完成，为后期高质量投产打 下坚实基础。 2020年，在这里，民间资本参股核电项目实现"破冰"，占股2%；去年8月，国务院核准包括浙江三澳二 期在内的五个核电项目，都引入了民间资本，且参股比例提高到了10%。国家发展改革委今年5月的数 据显示，有的核电项目民资参股比例已达20%。 "核电'大门'向民间资本越开越大，不仅给予核电产业链民营企业直接投资机会，也有利于整个产业链 协同发展，有利于促进民间投资在发展新质生产 ...

S1130525070007 1 风险提示：测算模型失效风险；重仓股补全与实际差异较大风险；基金持仓、久期大幅度偏离的风险。基金相关信息及数据仅作为基金研究 使用，不作为募集材料或者宣传材料；本文涉及所有基金历史业绩均不代表未来表现 2 • 本周（2025/07/07-2025/ 07/11，下同），沪深300上涨0.82%，主动股票及偏股混合基金整体测算股票仓位上升0.24%，至87.45% 。 • 本周主动股票及偏股混合型基金前5大行业：电子（13.65%）、电力设备（8.70%）、医药生物（7.16%）、汽车（6.54%）、机械设备（5.37%）。 • 加仓前3大行业：通信(+0.36%）、建筑材料(+0.20%）、有色金属(+0.12%）；减仓前3大行业：综合(-0.21%）、国防军工(-0.19%）、医药生物(- 0.15%）。 • 本周中债10年期国开债到期收益率上行3bps，中长期纯债整体测算久期中位数上升0.26，至3.31年，位于近5年的99.40%分位数。近4周平均久期 中位数为3.26年；本周久期分歧度有所上升，测算久期标准差上升0.10，至1.69年。短期纯债久期中位数上升0.30，至 ...

【导读】7月14日发布的《景顺全球主权资产管理研究》显示，全球主权投资机构对中国市场的兴趣显著提升 7月14日，美国资产管理巨头景顺发布的《全球主权资产管理研究》显示，全球主权投资机构对中国市场的兴趣上升，多数主权投资机构计划未来五年增 加对中国市场的配置。主权投资机构认可中国的科技创新能力，并认为在绿色转型领域中国是名副其实的领导者。 这是景顺第13年发布全球主权资产管理研究报告，相关调查于2025年1月—2025年3月间开展，覆盖141家全球主权投资机构，包括58家中央银行和83家主 权财富基金，合计管理规模达27万亿美元（约合193.51万亿元人民币）。今年的调查结果显示，59%的受访者表示，未来五年将增加对中国市场的配置。 73%的北美主权财富基金认为未来5年将增加对中国的配置 今年研究报告的一大亮点是，主权投资机构对中国的兴趣复苏。 例如，不少主权财富基金认为有充分理由看多中国，包括中国拥有具吸引力的本地回报、中国可提供多元化收益来源以及中国在关键技术领域崛起。 "我们的重点正转向中国的创新驱动型行业。我们将此视为在未来有望形成全球领导地位的领域建立敞口的机会。"一位中东投资者指出。 59%的受访主 ...

美股盘初，主要行业ETF涨跌不一，半导体ETF跌超1%，网络股指数ETF涨超0.5%。 | 半导体ETF - ... | 283.77 | -3.72 (-1.29%) 55.76万股 | | | --- | --- | --- | --- | | us SMH | | | | | 能源业ETF - ... | 88.54 | -0.59 (-0.66%) 155.90万股 | | | us XLE | | | | | 科技行业ET ... | 254.34 | -1.51 (-0.59%) | 27.86万股 | | us XLK | | | | | 全球科技股 ... | 92.69 | -0.55 (-0.59%) | 8023股 | | us IXN | | | | | 医疗业ETF - ... | 134.83 | -0.36 (-0.27%) | 87.57万股 | | us XLV | | | | | 生物科技指 ... | 131.37 | -0.22 (-0.17%) | 57942股 | | us IBB | | | | | 全球航空业E ... | 24.99 | -0.04 (-0.1 ...

近年来，生物制造已作为多数国家提升经济竞争力的着力点，也是我国继绿色制造、智能制造后，推进制造强国建设的又一重要抓手。同时，各地政府 地区通过结合自身优势力争实现合成生物"研发－转化－产业—集群"协同发展，发挥新质生产力 作用。 亮点一 ： 大会论坛、闭门活动洞察"十五五"生物制造发展趋势！探索新产品、新技术、新落地、 新合作！ 亮点二： 青年创新技术与价值分享、人才对接与合作！ 亮点三： 1 00+ 融资 项目路演、创新科技成果，发掘合作新机遇！ 亮点四： 头部企业、顶尖高校、园区资本、产业上下游齐聚！ 8月20-22日 将于 浙江·宁波 举 办 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2 025 ) 。大会 聚焦" 1+4 " ： AI+生 物智造 这一大热门赛道； 绿色化工与新材料、 未来食品、未来农业和美妆原料四大应用领域 ，邀请国 际领先企业、代表性产业化专家、政府、园 区、资本、协会和联盟等各方共探 "十五五"生物制造产业发展趋势 ； 哪些革新技术和产品将给生物制造产业带来持续的生命力 ； 并致力于 促进科技 成果转移转化 、 产品 规模 化与人才挖掘 。 一、组织机构 主 ...

Core Viewpoint - The article highlights the upcoming SynBioCon 2025 event, focusing on the potential of synthetic biology and biomanufacturing, showcasing innovative research teams, technologies, and products in the field [2][5][14]. Group 1: Event Overview - The SynBioCon 2025 will take place from August 20-22 in Ningbo, Zhejiang, featuring a special session called the "Biomanufacturing Youth Forum" with nearly 30 presentations [2][10]. - The event aims to facilitate the exchange of innovative research outcomes and promote collaboration between researchers and industry stakeholders [2][14]. Group 2: Forum Details - The Youth Forum will include presentations from various universities and research institutions, such as Anhui University of Technology and South China University of Technology [4][5]. - The forum is designed to help attendees understand key scientific issues, solutions, and future development directions in biomanufacturing within a 15-minute format [3][14]. Group 3: Special Activities - A closed-door high-level seminar will discuss the trends and growth points of biomanufacturing as part of the event's agenda [11]. - The event will also feature project roadshows and technology showcases, inviting participation from leading parks and investment institutions [14][20]. Group 4: Thematic Discussions - The conference will cover various topics, including green chemicals, new materials, AI in biomanufacturing, and future food and agriculture [15][17][19]. - Specific focus areas include the development of bio-based materials, non-grain carbon source utilization, and the application of AI in enhancing biomanufacturing processes [18][22].

绿色化工和新材料 | 中科院青岛能源所 利用微生物发酵一碳气体生产生物燃料及化学品，是当今实现碳资源捕捉利用和绿色生物制造的重要途径之一。CO 2 和CO、甲烷、甲醇以及甲酸等含有 一个碳原子的物质被称为一碳（one carbon，C 1 ）资源，其来源广泛且价格低廉，有望成为生物制造的替代原料。C 1 原料生物转化有助于缓解温室 效应、助力"碳中和"目标。 【SynBioCon】 获 悉，近日， 中国科学院青岛生物能源与过程 研究所李福利研究员等人 在《化工进展》 上发表 《以CO2为原料的第三代生物炼 制现状 》 一文。 文章总结了近年来以CO 2 为原料通过微生物炼制生产重要能源和化学品的研究进展，论述CO 2 的生物代谢途径以及产物合成途径，讨论以CO 2 为原 料的C 1 生物炼制中微生物的工程化改造，并展望未来绿色生物制造的新路线。 化石能源的使用与开发带动了现代工业蓬勃发展，但同时排放了大量二氧化碳（CO 2 ），加剧温室效应，造成全球变暖等气候问题。CO 2 、CO和CH 4 等同 属于一碳气体，主要源于化石燃料的不完全燃烧，如生物质气化、生活废气和冶炼等重工业生产的尾气。据《BP世界能源展望 ...